Heart transplantation successfully treated one patient with Danon disease, a frequently fatal condition, with more than 5 years of follow-up.
Case Report (n=8)
No
Can heart transplantation successfully treat lethal cardiomyopathy in patients with Danon disease?
Danon disease is a frequently fatal genetic condition causing lethal cardiomyopathy that can be successfully treated with heart transplantation.
Lysosome-associated membrane protein-2 deficiency (LAMP-2 deficiency), or Danon disease, is a rare X-linked lysosomal disease characterized by cardiomyopathy, vacuolar myopathy, and mental retardation. Less than 20 families with mutations of the Lamp-2 gene have been reported. We describe a family from Sardinia with eight affected patients (4 females and 4 males) and a novel mutation in exon 2 of the Lamp-2 gene (c. 102₁03delAG). Females developed isolated cardiomyopathy in adulthood, whereas males presented with cardiomyopathy, myopathy, and mental retardation before the age of 20 years. Cardiomyopathy was lethal in three females in their 40s and in three males before the age 20 years. One patient was successfully treated by heart transplantation with more than 5-year follow-up. This study demonstrates that Danon disease is a frequently fatal condition that is potentially treatable with heart transplantation.
Echaniz‐Laguna et al. (Wed,) conducted a case report in Danon disease (LAMP-2 deficiency) (n=8). Heart transplantation was evaluated on Survival and clinical outcome. Heart transplantation successfully treated one patient with Danon disease, a frequently fatal condition, with more than 5 years of follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: